iPS Cells & Regenerative Medicine– category –
-
BioInformant Analyzes the Rise of Exosome Therapeutics in 2026: Potential as a Novel Modality Leveraging Intercellular Communication for New Treatments
BioInformant (Blog) USA Overview BioInformant's blog analyzes the growing role of exosome therapeutics in 2026, highlighting these extracellular vesicles as an emerging treatment modality. Exosomes, lipid bilayer vesicles 30-150 nanomete... -
US FDA Reports Approximately 50% Approval Rate for Regenerative Medicine Advanced Therapy (RMAT) Designations, Totaling 193 Approvals Out of 388 Applications, Highlighting Accelerated Development in Regenerative Medicine
BioInformant (Blog) USA Overview According to a BioInformant blog post, the U.S. FDA has announced the approval of 193 out of 388 total Regenerative Medicine Advanced Therapy (RMAT) designation applications received to date. This indicat... -
University of Wisconsin-Madison Researchers Develop Platform to Identify Host Genes Hindering CRISPR Editing Efficiency, Paving Way for Enhanced Gene Therapy Efficacy
News-Medical.Net USA Overview A research team at the University of Wisconsin-Madison has developed an innovative platform to systematically identify specific host genes that impede the efficiency of CRISPR gene editing. This study provid... -
China’s Xellsmart Secures FDA Fast Track for Off-the-Shelf Stem Cell Therapy XS411 in Parkinson’s Disease, Demonstrating Efficacy in Early-Stage Patients in Chinese Phase 1/2 Trial
Endpoints News China Overview China-based Xellsmart's off-the-shelf stem cell therapy, XS411, for Parkinson's disease, has received FDA Fast Track designation. XS411 aims to replace lost dopamine-producing neurons and restore neurologica... -
FDA Approves Orca-T Precision Treg Cell Therapy, Reducing Chronic GVHD Risk and Boosting Survival in Blood Cancer Patients Undergoing Matched Donor Transplants
AJMC (American Journal of Managed Care) USA Overview The U.S. FDA has approved Orca-T precision Treg cell therapy, designed to reduce the risk of chronic graft-versus-host disease (GVHD) and improve survival rates in blood cancer patient... -
Bristol Myers Squibb’s First CELMoD Therapy ZENBEXUS™ (iberdomide) Receives FDA Accelerated Approval in Combination with Daratumumab for Multiple Myeloma Patients with Early Relapse
Bristol Myers Squibb (Press Release) USA Overview Bristol Myers Squibb announced that its innovative CELMoD therapy, ZENBEXUS™ (iberdomide), received accelerated approval from the U.S. FDA for multiple myeloma, in combination with daratu... -
City of Hope Reports Groundbreaking Phase 1 Data for CD19 CAR T-Cell Therapy in High-Risk ALL Patients, Achieving 84% 18-Month Event-Free Survival with Low Toxicity
Evaluate (Oncology Newsletter) USA Overview Researchers at City of Hope presented pivotal Phase 1 data for a CD19 CAR T-cell therapy in acute lymphoblastic leukemia (ALL), demonstrating an impressive 84% 18-month event-free survival rate... -
Keio University Publishes Long-Term Safety Data in Nature Medicine for iPSC-Derived Neural Stem Cell Transplant in Spinal Cord Injury: No Tumor Formation or Serious Adverse Events Over Four Years
OmniGenix Japan Overview A research team at Keio University has published groundbreaking long-term safety data in Nature Medicine from the world's first clinical study of iPSC-derived neural stem cell transplantation for spinal cord inju... -
Japan Marks 20th Anniversary of iPSC Discovery with World’s First Regenerative Medicine Product Approvals: Myocardial Cell Sheets for Severe Heart Failure and Neural Progenitor Cell Transplants for Parkinson’s Disease
Japan Science and Technology Agency (JST) Japan Overview Twenty years after Professor Shinya Yamanaka's discovery of iPS cells at Kyoto University in 2006, Japan achieved a global first with the approval of iPSC-derived regenerative medi... -
Aspen Neuroscience’s Personalized Cell Therapy Sasineprocel (ANPD001) Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Parkinson’s Disease
Longevity.Technology USA Overview Aspen Neuroscience announced that sasineprocel (ANPD001), its personalized cell therapy for Parkinson's disease, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA...
